secwatch.observer — SEC 8-K summary
======================================

Issuer:     TherapeuticsMD, Inc. (TXMD)
CIK:        0000025743
Form:       8-K
Filed at:   2023-01-03T23:59:59+00:00
Accession:  0001193125-23-000222
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.01, 1.02, 2.01, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TherapeuticsMD closes transaction with Mayne Pharma; receives $153M upfront, pays down debt and redeems preferred stock
--------------------------------------------------------------------------------

- Total upfront cash of ~$153.1M ($140M license/sale + $13.1M for working capital and prepaid royalties).
- Eligible for up to $30M in sales milestones and royalties of 7.5%–8% on net sales for 20 years (minimum $3M/yr for 12 years).
- Proceeds used to repay all debt under Sixth Street facility and redeem all 29,000 Series A Preferred shares at $1,333 each.
- Directors Bisaro, Ling, Musing, Russell resigned; Marlan Walker appointed Principal Executive Officer.
- Paid ~$3M make-whole to Rubric Capital Management affiliates per subscription agreements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/25743/000119312523000222/0001193125-23-000222-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/25743/000119312523000222/d417698d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-000222

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer